Nanomedicine for cancer

Rapid development of biomedical nanotechnology holds great promise to modify and improve various diagnostic and therapeutic strategies against cancer. Nanomedicine products make it possible to achieve highly specific tumor targeting and provide multi-functionality both, in terms of their loading with different drugs and diagnostic markers and in terms of their responsiveness to local tumor-specific stimuli. They can significantly improve properties and efficacy of various conventional therapeutics and bring to life a new generation of anti-cancer agents.

Biography

Vladimir Torchilin is University Distinguished Professor and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. He has published more than 350 original papers, more than 150 reviews and book chapters, wrote and edited 10 books and holds more than 40 patents. He is Editor-in-Chief of Current Drug Discovery Technologies and of Drug Delivery. He is a Member of European Academy of Sciences, Fellow of AIMBE, AAPS and CRS, and received many important national and international awards including the 2013 Blaise Pascal Medal in Biomedicine from EAS. In 2005, he was a President of the CRS and in 2011 Times Higher Education ranked him number 2 among top world scientists in pharmacology for 2001-2010.